Expert consensus on treating HR+/HER2- metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists

By sjmartinez • May 10, 2025

Rugo HS, Bardia A, Gradishar WJ, Hamilton EP, Hurvitz SA, Jhaveri K, Mahtani R, Tolaney SM. Expert consensus on treating HR+/HER2- metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists. Breast. 2025 May 3;82:104485. doi: 10.1016/j.breast.2025.104485. Epub ahead of print. PMID: 40344957.

Tags: Biomarker testing, Hematology/Oncology, Hormone receptor, Human epidermal growth factor receptor, metastatic breast cancer, Practice guidelines, Publications, side effects, treatment patterns

RINGSIDE Phase II Study of Varegacestat for Treatment of Desmoid Tumors: A Randomized Dose-Finding Clinical Trial

Chugh R, Singh A, Andelkovic V, Mallick AB, Brockstein B, Bui N, Chawla S, Choy E, Davis LE, Gounder M, Haddadin S, Kasper B, Kim[...]

Androgen receptor inhibitor double therapies in the management of metastatic castration-sensitive prostate cancer: a cost-effectiveness analysis

Padula WV, Cohen BG, Steel P, Appukkuttan S, Kalayeh B, Rettig M. Androgen receptor inhibitor double therapies in the management of metastatic castration-sensitive prostate cancer:[...]

tRNA dosage regulates lineage dependency and resistance in prostate cancer

Kim YS, Arora S, Young D, Tsou A, Shiuan A, Wladyka CL, Rudoy D, Kim JY, Waters JA, Schuster SL, Coleman IM, Kapur M, Sobczyk[...]